Xilio Therapeutics (XLO) Total Liabilities (2020 - 2026)

Xilio Therapeutics has disclosed Total Liabilities across 7 years of filings, most recently posting $82.0 million for Q2 2026.

• In Q2 2026, Total Liabilities fell 35.31% year-over-year to $82.0 million; the TTM figure through Jun 2026 stood at $82.0 million (down 35.31% YoY), while the FY2025 annual figure was $119.4 million, up 123.3% from the prior year.
• Total Liabilities came in at $82.0 million for Q2 2026 at Xilio Therapeutics, down from $90.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $141.8 million in Q3 2025 to a low of $24.1 million in Q4 2023.
• Average Total Liabilities over 5 years is $61.3 million, with a median of $53.6 million recorded in 2024.
• Year-over-year, Total Liabilities sank 72.05% in 2022 and jumped 164.12% in 2025.
• Over 5 years, Total Liabilities stood at $33.5 million in 2022, then slipped by 28.1% to $24.1 million in 2023, then soared by 121.91% to $53.5 million in 2024, then soared by 123.3% to $119.4 million in 2025, then tumbled by 31.34% to $82.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $82.0 million in Q2 2026, $90.9 million in Q1 2026, and $119.4 million in Q4 2025.